Radiopharm Theranostics (RADX) Competitors

$4.25 -0.34 (-7.41%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 +0.05 (+1.08%)

As of 07:15 PM Eastern

RADX vs. ELTX, NKTX, SABS, TKNO, and LFCR

Should you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Elicio Therapeutics (ELTX), Nkarta (NKTX), SAB Biotherapeutics (SABS), Alpha Teknova (TKNO), and Lifecore Biomedical (LFCR). These companies are all part of the "med - biomed/gene" industry.

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

: Radiopharm Theranostics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Elicio Therapeutics N/A -977.66% -141.55%
Radiopharm Theranostics N/A N/A N/A
: 35.0% of Elicio Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Elicio Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 72.25%. Radiopharm Theranostics has a consensus price target of $16.00, suggesting a potential upside of 276.47%. Given Radiopharm Theranostics' higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than Elicio Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.75
Radiopharm Theranostics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
: In the previous week, Elicio Therapeutics had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Elicio Therapeutics and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.84 beat Elicio Therapeutics' score of -0.13 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.
Company Overall Sentiment
Elicio Therapeutics Neutral
Radiopharm Theranostics Positive
: Radiopharm Theranostics has higher revenue and earnings than Elicio Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Elicio Therapeutics N/A N/A -$39.57M -$2.62 N/A
Radiopharm Theranostics $2.35M 21.36 -$24.83M N/A N/A
: Elicio Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Radiopharm Theranostics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-977.66%	-141.55%
Radiopharm Theranostics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Radiopharm Theranostics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.62	N/A
Radiopharm Theranostics	$2.35M	21.36	-$24.83M	N/A	N/A

Summary

Radiopharm Theranostics beats Elicio Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

: Radiopharm Theranostics' return on equity of 0.00% beat Nkarta's return on equity.
Company Net Margins Return on Equity Return on Assets
Nkarta N/A -30.02% -23.78%
Radiopharm Theranostics N/A N/A N/A
: 80.5% of Nkarta shares are owned by institutional investors. 8.4% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Nkarta currently has a consensus price target of $11.33, suggesting a potential upside of 241.37%. Radiopharm Theranostics has a consensus price target of $16.00, suggesting a potential upside of 276.47%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than Nkarta.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nkarta
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Radiopharm Theranostics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
: In the previous week, Nkarta had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Nkarta and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.84 beat Nkarta's score of 0.51 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.
Company Overall Sentiment
Nkarta Positive
Radiopharm Theranostics Positive
: Radiopharm Theranostics has higher revenue and earnings than Nkarta.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nkarta N/A N/A -$104.08M -$1.40 N/A
Radiopharm Theranostics $2.35M 21.36 -$24.83M N/A N/A
: Nkarta has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Radiopharm Theranostics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.02%	-23.78%
Radiopharm Theranostics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Overall Sentiment
Nkarta	Positive
Radiopharm Theranostics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.40	N/A
Radiopharm Theranostics	$2.35M	21.36	-$24.83M	N/A	N/A

Summary

Radiopharm Theranostics beats Nkarta on 9 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

: SAB Biotherapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Radiopharm Theranostics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
: SAB Biotherapeutics has higher earnings, but lower revenue than Radiopharm Theranostics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAB Biotherapeutics $1.32M 146.67 $13.27M -$2.32 N/A
Radiopharm Theranostics $2.35M 21.36 -$24.83M N/A N/A
: SAB Biotherapeutics presently has a consensus target price of $10.50, indicating a potential upside of 176.32%. Radiopharm Theranostics has a consensus target price of $16.00, indicating a potential upside of 276.47%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than SAB Biotherapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics
2 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
Radiopharm Theranostics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
: In the previous week, SAB Biotherapeutics had 6 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.84 beat SAB Biotherapeutics' score of 0.67 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.
Company Overall Sentiment
SAB Biotherapeutics Positive
Radiopharm Theranostics Positive
: 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: SAB Biotherapeutics' return on equity of 15.17% beat Radiopharm Theranostics' return on equity.
Company Net Margins Return on Equity Return on Assets
SAB Biotherapeutics N/A 15.17% 12.51%
Radiopharm Theranostics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	146.67	$13.27M	-$2.32	N/A
Radiopharm Theranostics	$2.35M	21.36	-$24.83M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Overall Sentiment
SAB Biotherapeutics	Positive
Radiopharm Theranostics	Positive

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	15.17%	12.51%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

SAB Biotherapeutics beats Radiopharm Theranostics on 8 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Alpha Teknova?

Radiopharm Theranostics (NASDAQ:RADX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

: Radiopharm Theranostics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
: Radiopharm Theranostics has a net margin of 0.00% compared to Alpha Teknova's net margin of -42.59%. Radiopharm Theranostics' return on equity of 0.00% beat Alpha Teknova's return on equity.
Company Net Margins Return on Equity Return on Assets
Radiopharm Theranostics N/A N/A N/A
Alpha Teknova -42.59% -23.32% -15.85%
: Alpha Teknova has higher revenue and earnings than Radiopharm Theranostics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radiopharm Theranostics $2.35M 21.36 -$24.83M N/A N/A
Alpha Teknova $40.52M 4.82 -$17.26M -$0.33 N/A
: In the previous week, Alpha Teknova had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Alpha Teknova and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.84 beat Alpha Teknova's score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media.
Company Overall Sentiment
Radiopharm Theranostics Positive
Alpha Teknova Neutral
: Radiopharm Theranostics currently has a consensus target price of $16.00, suggesting a potential upside of 276.47%. Alpha Teknova has a consensus target price of $8.00, suggesting a potential upside of 119.78%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than Alpha Teknova.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Radiopharm Theranostics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
Alpha Teknova
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
: 13.8% of Alpha Teknova shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Alpha Teknova	-42.59%	-23.32%	-15.85%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.36	-$24.83M	N/A	N/A
Alpha Teknova	$40.52M	4.82	-$17.26M	-$0.33	N/A

Company	Overall Sentiment
Radiopharm Theranostics	Positive
Alpha Teknova	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Radiopharm Theranostics beats Alpha Teknova on 9 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Radiopharm Theranostics (NASDAQ:RADX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

: Radiopharm Theranostics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
: Radiopharm Theranostics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -23.08%. Radiopharm Theranostics' return on equity of 0.00% beat Lifecore Biomedical's return on equity.
Company Net Margins Return on Equity Return on Assets
Radiopharm Theranostics N/A N/A N/A
Lifecore Biomedical -23.08% -1,211.09% -9.69%
: Radiopharm Theranostics has higher earnings, but lower revenue than Lifecore Biomedical.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radiopharm Theranostics $2.35M 21.36 -$24.83M N/A N/A
Lifecore Biomedical $128.87M 1.44 -$36.73M -$0.98 N/A
: In the previous week, Lifecore Biomedical had 9 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 9 mentions for Lifecore Biomedical and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.84 beat Lifecore Biomedical's score of 0.43 indicating that Radiopharm Theranostics is being referred to more favorably in the media.
Company Overall Sentiment
Radiopharm Theranostics Positive
Lifecore Biomedical Neutral
: Radiopharm Theranostics currently has a consensus target price of $16.00, suggesting a potential upside of 276.47%. Lifecore Biomedical has a consensus target price of $6.00, suggesting a potential upside of 20.97%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Radiopharm Theranostics is more favorable than Lifecore Biomedical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Radiopharm Theranostics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
Lifecore Biomedical
1 Sell rating(s)

2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.20
: 83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Lifecore Biomedical	-23.08%	-1,211.09%	-9.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.36	-$24.83M	N/A	N/A
Lifecore Biomedical	$128.87M	1.44	-$36.73M	-$0.98	N/A

Company	Overall Sentiment
Radiopharm Theranostics	Positive
Lifecore Biomedical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Radiopharm Theranostics beats Lifecore Biomedical on 10 of the 15 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.19M	$3.42B	$6.28B	$12.14B
Dividend Yield	N/A	2.23%	2.74%	5.25%
P/E Ratio	N/A	39.00	29.30	27.36
Price / Sales	21.36	293.74	492.56	76.98
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	1.21	7.20	9.78	6.76
Net Income	-$24.83M	$23.57M	$3.55B	$332.77M
7 Day Performance	-2.30%	7.22%	3.90%	4.25%
1 Month Performance	-3.85%	7.64%	6.04%	9.11%
1 Year Performance	1.19%	81.29%	40.49%	43.80%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	3.7178 of 5 stars	$4.25 -7.4%	$16.00 +276.5%	+9.3%	$50.19M	$2.35M	N/A	N/A
ELTX Elicio Therapeutics	1.7875 of 5 stars	$10.75 +1.2%	$18.00 +67.4%	+92.5%	$198.65M	N/A	N/A	N/A	Upcoming Earnings
NKTX Nkarta	3.0554 of 5 stars	$2.93 +5.8%	$11.33 +286.8%	+55.6%	$197.48M	N/A	N/A	140	Upcoming Earnings
SABS SAB Biotherapeutics	2.8036 of 5 stars	$3.47 -7.2%	$10.50 +202.6%	+116.5%	$190.56M	$1.32M	N/A	140	Upcoming Earnings
TKNO Alpha Teknova	2.0857 of 5 stars	$3.40 -4.2%	$8.00 +135.3%	-37.8%	$190.32M	$40.52M	N/A	240	News Coverage Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. ELTX, NKTX, SABS, TKNO, and LFCR

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Summary

How does Radiopharm Theranostics compare to Nkarta?

Summary

How does Radiopharm Theranostics compare to SAB Biotherapeutics?

Summary

How does Radiopharm Theranostics compare to Alpha Teknova?

Summary

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. ELTX, NKTX, SABS, TKNO, and LFCR

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Summary

How does Radiopharm Theranostics compare to Nkarta?

Summary

How does Radiopharm Theranostics compare to SAB Biotherapeutics?

Summary

How does Radiopharm Theranostics compare to Alpha Teknova?

Summary

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools